All In Biotech

Investigational drug · Phase 3

SYHA1813

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Unresectable Locally Advanced or Metastatic Solid Tumors, High Grade Meningioma, Recurrent or Progressive High Grade Meningioma.

Phase 3

Last checked: Nov 19, 2026Latest source record: May 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

4

Any phase or sponsor naming "SYHA1813"

First trial start

2024

Nov 13, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "SYHA1813", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Unresectable Locally Advanced or Metastatic Solid Tumors
  • High Grade Meningioma
  • Recurrent or Progressive High Grade Meningioma

Approved drugs for the same conditions: Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "SYHA1813" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 8 on PubMed

Also in development for Unresectable Locally Advanced or Metastatic Solid Tumors

  • SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • IBI3014Phase 21 trial

    Innovent Biologics (Suzhou) Co. Ltd. · Unresectable Locally Advanced or Metastatic Solid Tumors

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.